Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T37308
(Former ID: TTDS00132)
|
|||||
| Target Name |
Immunoglobulin E (IgE)
|
|||||
| Synonyms |
IgE
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Spontaneous urticaria [ICD-11: EB00] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
| 1 | Ligelizumab | Drug Info | Phase 3 | Chronic idiopathic urticaria | [2] | |
| 2 | MEMP1972A | Drug Info | Phase 2 | Allergic rhinitis | [3] | |
| 3 | AVP-13358 | Drug Info | Phase 1 | Rhinitis | [4] | |
| 4 | MEDI4212 | Drug Info | Phase 1 | Asthma | [5] | |
| 5 | PF-06444752 | Drug Info | Phase 1 | Asthma | [6] | |
| 6 | Xmab-7195 | Drug Info | Phase 1 | Asthma | [7] | |
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | TAK-201 | Drug Info | Discontinued in Phase 2 | Allergy | [8] | |
| 2 | IGE-026 | Drug Info | Terminated | Allergic rhinitis | [9] | |
| 3 | TEI-9874 | Drug Info | Terminated | Allergy | [10] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 4 Inhibitor drugs | + | ||||
| 1 | Ligelizumab | Drug Info | [11] | |||
| 2 | AVP-13358 | Drug Info | [12] | |||
| 3 | Xmab-7195 | Drug Info | [15] | |||
| 4 | IGE-026 | Drug Info | [17] | |||
| Modulator | [+] 4 Modulator drugs | + | ||||
| 1 | MEDI4212 | Drug Info | [13] | |||
| 2 | PF-06444752 | Drug Info | [6], [14] | |||
| 3 | TAK-201 | Drug Info | [16] | |||
| 4 | TEI-9874 | Drug Info | [18] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011 | |||||
| REF 2 | ClinicalTrials.gov (NCT04210843) Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT01582503) A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA). U.S. National Institutes of Health. | |||||
| REF 4 | AVANIR Reports Positive Interim Phase I Safety Data on Asthma/Allergy Drug Candidate; Potential Asthma/Allergy Product Modulates IgE and Th2 Cytokines Orally | |||||
| REF 5 | ClinicalTrials.gov (NCT01544348) A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL. U.S. National Institutes of Health. | |||||
| REF 6 | ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health. | |||||
| REF 7 | ClinicalTrials.gov (NCT02148744) Safety and Tolerability of XmAb7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis. U.S. National Institutes of Health. | |||||
| REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031068) | |||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017769) | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012536) | |||||
| REF 11 | Clinical pipeline report, company report or official report of Novartis. | |||||
| REF 12 | Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. | |||||
| REF 13 | A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64. | |||||
| REF 14 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 15 | Clinical pipeline report, company report or official report of Xencor. | |||||
| REF 16 | Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. | |||||
| REF 17 | IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5. | |||||
| REF 18 | Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95. | |||||
| REF 19 | Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.